Bisphosphonate long-term treatment related bilateral subtrochanteric femoral fracture. Can teriparatide be useful?

被引:15
作者
Jose Tarazona-Santabalbina, Francisco [1 ]
Aguilella-Fernandez, Luis [2 ]
机构
[1] Hosp Univ Ribera, Geriatr Med Dept, Valencia 46600, Spain
[2] Hosp Univ Ribera, Dept Orthopaed, Valencia 46600, Spain
关键词
Hip fracture; Bisphosphonates; Long-term treatment; SUPPRESSED BONE TURNOVER; ALENDRONATE THERAPY; RANDOMIZED-TRIAL; SHAFT FRACTURES; SAFETY; WOMEN; COMPLICATION;
D O I
10.1007/s40520-013-0137-3
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Long-term treatment with biphosphonates has been related to atypical femoral fractures. We report the clinical case of a woman who suffered a proximal diaphyseal oblique fracture of the left femur after uninterrupted 13-year treatment with alendronate. Shortly after surgery, a painful lytic image in the external cortex of her right femur diaphysis was detected. Some papers have suggested surgical treatment to repair femur fractures after long-term treatment with bisphosphonates. Otherwise, two studies have shown healing acceleration of bone fractures with teriparatide. A lytic lesion was treated with teriparatide obtaining progressive disappearance of symptoms as well as bone healing. This outcome may suggest a way of prevention of complete fractures in symptomatic patients with long-term treatment with bisphosphonates.
引用
收藏
页码:605 / 609
页数:5
相关论文
共 30 条
[1]  
Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
[2]  
Bamrungsong Tachchai, 2010, Journal of the Medical Association of Thailand, V93, P620
[3]  
Black D, 2004, J BONE MINER RES, V19, pS45
[4]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[5]   Intravenous bisphosphonate therapy for osteoporosis: where do we stand? [J].
Bone H.G. ;
Schurr W. .
Current Osteoporosis Reports, 2004, 2 (1) :24-30
[6]  
Cheung Ralph K. H., 2007, Hong Kong Medical Journal, V13, P485
[7]   Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension [J].
Ensrud, KE ;
Barrett-Connor, EL ;
Schwartz, A ;
Santora, AC ;
Bauer, DC ;
Suryawanshi, S ;
Feldstein, A ;
Haskell, WL ;
Hochberg, MC ;
Torner, JC ;
Lombardi, A ;
Black, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1259-1269
[8]   Review of Osteoporosis Pharmacotherapy for Geriatric Patients [J].
Gates, Brian J. ;
Sonnett, Travis E. ;
DuVall, Cristina A. K. ;
Dobbins, Erin K. .
AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (06) :293-323
[9]  
Goddard Maria S, 2009, Orthopedics, V32, DOI 10.3928/01477447-20090624-27
[10]   Subtrochanteric insufficiency fractures in patients on alendronate therapy - A caution [J].
Goh, S.-K. ;
Yang, K. Y. ;
Koh, J. S. B. ;
Wong, M. K. ;
Chua, S. Y. ;
Chua, D. T. C. ;
Howe, T. S. .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2007, 89B (03) :349-353